Robecosam AG boosted its stake in Boston Scientific Co. (NYSE:BSX) by 2.0% during the 4th quarter, HoldingsChannel reports. The firm owned 493,804 shares of the medical equipment provider’s stock after buying an additional 9,903 shares during the quarter. Robecosam AG’s holdings in Boston Scientific were worth $12,439,000 at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Truewealth LLC bought a new stake in shares of Boston Scientific in the 4th quarter worth about $116,000. Icon Wealth Partners LLC bought a new stake in shares of Boston Scientific in the 4th quarter worth about $117,000. Cerebellum GP LLC bought a new stake in shares of Boston Scientific in the 4th quarter worth about $126,000. Delpha Capital Management LLC bought a new stake in shares of Boston Scientific in the 4th quarter worth about $135,000. Finally, Valeo Financial Advisors LLC bought a new stake in shares of Boston Scientific in the 3rd quarter worth about $138,000. Hedge funds and other institutional investors own 91.85% of the company’s stock.
In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 85,227 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $26.48, for a total value of $2,256,810.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael P. Phalen sold 15,835 shares of the business’s stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $25.25, for a total transaction of $399,833.75. The disclosure for this sale can be found here. Over the last three months, insiders sold 174,276 shares of company stock valued at $4,592,464. 0.74% of the stock is owned by corporate insiders.
Shares of Boston Scientific Co. (NYSE:BSX) opened at $28.54 on Tuesday. The stock has a market cap of $39,240.00, a PE ratio of 40.77, a price-to-earnings-growth ratio of 2.06 and a beta of 0.82. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.68 and a quick ratio of 0.49. Boston Scientific Co. has a 52-week low of $24.02 and a 52-week high of $29.93.
Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.34. The company had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.39 billion. Boston Scientific had a net margin of 1.15% and a return on equity of 24.27%. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.30 EPS. equities research analysts anticipate that Boston Scientific Co. will post 1.37 earnings per share for the current year.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.